---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-010419"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T21:01:20.188024+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Palatin initiates Phase 2 study of bremelanotide/PDE5i combo for ED non-responders

## Summary
- Approximately 30–40% of ED patients do not respond to PDE5i monotherapy.
- Phase 2 trial of bremelanotide co-formulated with a PDE5i expected to start Q4 2023.
- Published data show synergy between bremelanotide and PDE5i via distinct mechanisms.
- Bremelanotide is the active agent in Vyleesi, approved for HSDD in women.
- Palatin successfully co-formulated bremelanotide with a PDE5i for single injection.

## SEC filing metadata
- accession: 0001654954-23-010419
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495423010419/0001654954-23-010419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495423010419/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-010419
- JSON: https://secwatch.observer/filing/0001654954-23-010419.json
- Plain text: https://secwatch.observer/filing/0001654954-23-010419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.